IFNA1 and acquired polycythemia vera: A large randomized trial conducted by the Myeloproliferative Disorders Research Consortium is currently being performed throughout the United States and Europe comparing HU and pegylated (PEG)-IFN-α-2-a in the treatment of patients with high-risk PV.